From Alchemy to IPO: The Business of Biotechnology
May 6, 2010 by biotechbillboard.com
- ISBN13: 9780738204826
- Condition: NEW
- Notes: Brand New from Publisher. No Remainder Mark.
Product Description
A fascinating glimpse inside the life-and-death business of biotechnology.
“A tour-de-force for anyone who is interested in the biotech industry. I applaud the enormous achievement of Cynthia Robbins-Roth.” -Frederick Frank, Senior Managing Director & Vice Chair, Lehman Brothers
“From Alchemy to IPO tells the dramatic story of this revolutionary industry as only an insider can.” -George Rathmann, President and CEO, ICOS Corporation, Chairman Emeritus, Amgen
Written by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the seventies to today’s heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market. This is the first book to accurately record the inner workings of an industry-biotechnology-that’s on the verge of living up to its monumental promise to change the world as we know it.Amazon.com Review
Despite unnerving swings in individual stock valuations–or perhaps because of them–many knowledgeable observers still believe the 21st century will ultimately earn its stripes as the Age of Biotech. Cynthia Robbins-Roth, named by Forbes magazine as one of the industry’s top insiders, certainly is among them. And in From Alchemy to IPO, she persuasively argues investors better take heed because they ain’t seen nothin’ yet. “Most of us think of biotech as medicine or genetically engineered crops,” writes Robbins-Roth. But in the very near future, she continues, it also “may make it possible for humans to reach the stars and to change the environment on other planets.” Think that’s far-fetched? She says developments like this are already in early stages and, in a deliberately proselytizing manner, traces their roots to the current business nitty-gritty, finally focusing on the long-term moneymaking potential. “The biotech world will never be an easy place for investors,” she cautions, but with hundreds of ongoing projects “poised to power into the marketplace,” there will be plenty of “opportunities for investors and employees alike.” Recommended for readers seeking an informed tutorial on this field of the future. –Howard Rothman
Buy from AMAZON From Alchemy to IPO: The Business of Biotechnology
For someone interested in investing in Biotech and wanting to do homework, this a great book to start with. I have read it twice.
Rating: 4 / 5
This is a great overview of the world of biotech. The author explains the science with clarity and enthusiasm and the introduction this book provides to the corporate side of biotech is also very interesting and well written.
Rating: 4 / 5
I am a student planning on majoring in molecular biology, with the goal of getting into a biotechnology company. I thought that this book was going to have a little more technical information, but I found that it was mainly a book geared towards investors, not students, or scientists. It has a lot of interesting information on how companies start up, and stock info, but this book is definately not for a person who is mainly interested in the science.
Rating: 3 / 5
Thanks to the Owen’s Reads for sending me a truly Like New book that is a great read. I’m using this for an online Management class, as if textbooks weren’t dry enough! I was pleasantly surprised by the novel-style writing of this book that made all the facts and figures engaging, bringing them to life. Best read I’ve had to do classes all year!
Rating: 5 / 5
I very much enjoyed how this identifies to the reader the back office complexities (made simple and easy to understand) that you never hear about and the process, including time it takes for a molecule to make it to market (assuming it does, which this book also explains well).
Overall, an excellent resource to anyone interested in the Biotech Industry’s business end and investment strategies.
Rating: 5 / 5